Cofactor leverages the power of RNA to model disease. We build expression models to interpret dynamic, complex data that define health state. These models are a quantitative global representation of gene expression. Today, our technology is being leveraged to model Immune Cells in Cofactor's product ImmunoPrism. ImmunoPrism is an immune profiling assay that overcomes the limitations with previous technologies. ImmunoPrism is available as a clinical assay as well as a research kit for use in the thousands of labs profiling tumors. Additional kits and clinical assays built on Cofactor's Prism Database of RNA models are slated for future release. Cofactor is leveraging its database of RNA models to predict drug response for the 95% of diseases that cannot be assessed by DNA alone. According to the NCI, 50% of the world's population will have cancer, and 25% will eventually die from it. Cofactor's team of former Human Genome Project Scientists are on a mission to significantly change those stats!